Trial Profile
An exploratory Phase I/II safety and tolerability clinical evaluation of VAL-1000 in adults with Acute Leukaemias
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Feb 2020
Price :
$35
*
At a glance
- Drugs VAL 1000 (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Senz Oncology
- 05 Feb 2020 Status changed from recruiting to discontinued.
- 25 Sep 2012 New trial record